| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 184 | 2026 | 712 | 34.990 |
Why?
|
| Tissue and Organ Procurement | 89 | 2026 | 343 | 20.650 |
Why?
|
| Tissue Donors | 77 | 2026 | 420 | 14.950 |
Why?
|
| Kidney Failure, Chronic | 75 | 2026 | 599 | 12.140 |
Why?
|
| Waiting Lists | 70 | 2026 | 266 | 11.870 |
Why?
|
| Graft Survival | 76 | 2026 | 519 | 8.930 |
Why?
|
| Organ Transplantation | 23 | 2025 | 253 | 6.980 |
Why?
|
| Living Donors | 55 | 2026 | 282 | 6.560 |
Why?
|
| Liver Transplantation | 25 | 2026 | 827 | 5.810 |
Why?
|
| Transplant Recipients | 23 | 2025 | 182 | 5.090 |
Why?
|
| Registries | 76 | 2026 | 2410 | 4.840 |
Why?
|
| Graft Rejection | 38 | 2025 | 521 | 4.270 |
Why?
|
| Renal Dialysis | 37 | 2026 | 466 | 4.220 |
Why?
|
| Lung Transplantation | 9 | 2025 | 332 | 3.860 |
Why?
|
| United States | 141 | 2026 | 16126 | 3.630 |
Why?
|
| Heart Transplantation | 10 | 2025 | 680 | 3.210 |
Why?
|
| Renal Insufficiency, Chronic | 33 | 2023 | 668 | 3.000 |
Why?
|
| Healthcare Disparities | 19 | 2025 | 736 | 2.990 |
Why?
|
| Quality Indicators, Health Care | 9 | 2018 | 336 | 2.730 |
Why?
|
| End Stage Liver Disease | 6 | 2025 | 95 | 2.720 |
Why?
|
| Transplants | 10 | 2022 | 38 | 2.650 |
Why?
|
| Humans | 369 | 2026 | 145783 | 2.620 |
Why?
|
| Donor Selection | 16 | 2025 | 79 | 2.540 |
Why?
|
| Middle Aged | 183 | 2026 | 36309 | 2.540 |
Why?
|
| Medicare | 17 | 2026 | 904 | 2.520 |
Why?
|
| Adult | 166 | 2026 | 40881 | 2.320 |
Why?
|
| Patient Selection | 10 | 2025 | 739 | 2.290 |
Why?
|
| Kidney | 34 | 2024 | 1497 | 2.240 |
Why?
|
| Resource Allocation | 5 | 2025 | 52 | 2.210 |
Why?
|
| Male | 227 | 2026 | 73011 | 2.180 |
Why?
|
| Health Services Accessibility | 18 | 2026 | 1101 | 2.150 |
Why?
|
| Risk Factors | 84 | 2026 | 10919 | 2.040 |
Why?
|
| Female | 219 | 2026 | 79045 | 1.950 |
Why?
|
| Aged | 131 | 2026 | 26217 | 1.930 |
Why?
|
| Treatment Outcome | 71 | 2026 | 11794 | 1.920 |
Why?
|
| Social Determinants of Health | 7 | 2026 | 309 | 1.890 |
Why?
|
| Glomerular Filtration Rate | 32 | 2024 | 765 | 1.830 |
Why?
|
| Retrospective Studies | 93 | 2026 | 17330 | 1.820 |
Why?
|
| Delayed Graft Function | 11 | 2026 | 46 | 1.790 |
Why?
|
| Postoperative Complications | 22 | 2026 | 2977 | 1.650 |
Why?
|
| Transplantation | 5 | 2024 | 33 | 1.580 |
Why?
|
| Program Evaluation | 8 | 2021 | 944 | 1.550 |
Why?
|
| Time Factors | 53 | 2026 | 7134 | 1.540 |
Why?
|
| Pancreas Transplantation | 10 | 2025 | 71 | 1.540 |
Why?
|
| Proportional Hazards Models | 34 | 2025 | 1330 | 1.480 |
Why?
|
| Prognosis | 36 | 2026 | 4330 | 1.380 |
Why?
|
| Heart Failure | 10 | 2024 | 2326 | 1.370 |
Why?
|
| Travel | 4 | 2020 | 136 | 1.350 |
Why?
|
| Follow-Up Studies | 41 | 2026 | 5428 | 1.310 |
Why?
|
| Nephrectomy | 11 | 2021 | 163 | 1.300 |
Why?
|
| Body Mass Index | 14 | 2024 | 2447 | 1.250 |
Why?
|
| Organ Preservation | 6 | 2026 | 125 | 1.160 |
Why?
|
| Patient Readmission | 6 | 2023 | 773 | 1.140 |
Why?
|
| Kidney Diseases | 11 | 2017 | 426 | 1.100 |
Why?
|
| Acute Kidney Injury | 12 | 2023 | 874 | 1.090 |
Why?
|
| Clinical Trials as Topic | 9 | 2025 | 1062 | 1.080 |
Why?
|
| Mycophenolic Acid | 9 | 2020 | 119 | 1.070 |
Why?
|
| Risk Assessment | 30 | 2025 | 3752 | 1.040 |
Why?
|
| Myasthenia Gravis | 5 | 2026 | 24 | 1.030 |
Why?
|
| Cold Ischemia | 6 | 2026 | 40 | 1.030 |
Why?
|
| Social Class | 2 | 2021 | 264 | 1.020 |
Why?
|
| Immunosuppressive Agents | 19 | 2020 | 838 | 1.010 |
Why?
|
| Health Expenditures | 6 | 2026 | 194 | 0.980 |
Why?
|
| Survival Rate | 23 | 2026 | 2094 | 0.980 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2025 | 971 | 0.970 |
Why?
|
| Transplantation, Heterologous | 2 | 2025 | 170 | 0.940 |
Why?
|
| Hospitals, Low-Volume | 2 | 2017 | 26 | 0.930 |
Why?
|
| Informed Consent | 2 | 2025 | 199 | 0.920 |
Why?
|
| Hospitals, High-Volume | 2 | 2017 | 50 | 0.910 |
Why?
|
| ABO Blood-Group System | 2 | 2025 | 58 | 0.910 |
Why?
|
| Mortality | 5 | 2019 | 381 | 0.900 |
Why?
|
| Surgicenters | 2 | 2016 | 5 | 0.900 |
Why?
|
| Severity of Illness Index | 13 | 2025 | 2933 | 0.890 |
Why?
|
| Tissue and Organ Harvesting | 7 | 2024 | 78 | 0.850 |
Why?
|
| Tacrolimus | 7 | 2013 | 196 | 0.840 |
Why?
|
| Adolescent | 51 | 2025 | 22577 | 0.830 |
Why?
|
| Solitary Kidney | 1 | 2023 | 2 | 0.810 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2024 | 61 | 0.810 |
Why?
|
| Life Expectancy | 2 | 2018 | 73 | 0.800 |
Why?
|
| Cadaver | 12 | 2025 | 311 | 0.790 |
Why?
|
| Hospital Records | 2 | 2013 | 10 | 0.790 |
Why?
|
| Young Adult | 37 | 2021 | 14254 | 0.790 |
Why?
|
| Congresses as Topic | 2 | 2024 | 224 | 0.780 |
Why?
|
| Cohort Studies | 28 | 2026 | 6033 | 0.740 |
Why?
|
| Developing Countries | 1 | 2024 | 317 | 0.730 |
Why?
|
| Electronic Health Records | 12 | 2021 | 1202 | 0.720 |
Why?
|
| Global Health | 2 | 2024 | 403 | 0.710 |
Why?
|
| Health Policy | 5 | 2016 | 400 | 0.710 |
Why?
|
| Perfusion | 5 | 2026 | 251 | 0.690 |
Why?
|
| Benchmarking | 2 | 2021 | 191 | 0.680 |
Why?
|
| Nephrology | 3 | 2021 | 60 | 0.680 |
Why?
|
| Cardiovascular Diseases | 6 | 2022 | 2191 | 0.650 |
Why?
|
| Health Facilities | 3 | 2018 | 85 | 0.640 |
Why?
|
| Nutrition Surveys | 4 | 2016 | 279 | 0.640 |
Why?
|
| Aged, 80 and over | 36 | 2026 | 8347 | 0.630 |
Why?
|
| Quality Improvement | 3 | 2019 | 1296 | 0.620 |
Why?
|
| Decision Making | 4 | 2025 | 982 | 0.620 |
Why?
|
| Renal Insufficiency | 5 | 2018 | 172 | 0.620 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 68 | 0.610 |
Why?
|
| Hospital Mortality | 7 | 2020 | 1038 | 0.600 |
Why?
|
| Kidney Calculi | 4 | 2021 | 44 | 0.590 |
Why?
|
| Cytomegalovirus Infections | 5 | 2024 | 206 | 0.580 |
Why?
|
| Ohio | 13 | 2018 | 146 | 0.580 |
Why?
|
| Residence Characteristics | 3 | 2025 | 375 | 0.560 |
Why?
|
| Isoantibodies | 5 | 2024 | 57 | 0.560 |
Why?
|
| Quality Assurance, Health Care | 4 | 2019 | 342 | 0.550 |
Why?
|
| Reoperation | 5 | 2015 | 637 | 0.550 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2015 | 64 | 0.540 |
Why?
|
| Continuity of Patient Care | 2 | 2024 | 297 | 0.530 |
Why?
|
| Hospitalization | 11 | 2023 | 2461 | 0.530 |
Why?
|
| Cause of Death | 10 | 2021 | 472 | 0.520 |
Why?
|
| BK Virus | 4 | 2014 | 18 | 0.520 |
Why?
|
| Incidence | 17 | 2025 | 2934 | 0.510 |
Why?
|
| Population Health | 1 | 2018 | 44 | 0.510 |
Why?
|
| Polyomavirus Infections | 4 | 2014 | 30 | 0.510 |
Why?
|
| Tumor Virus Infections | 4 | 2014 | 51 | 0.510 |
Why?
|
| Logistic Models | 15 | 2025 | 2139 | 0.500 |
Why?
|
| Emergency Service, Hospital | 11 | 2022 | 2383 | 0.500 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2017 | 303 | 0.500 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 271 | 0.490 |
Why?
|
| Hospitals | 4 | 2020 | 733 | 0.490 |
Why?
|
| HLA Antigens | 4 | 2011 | 240 | 0.480 |
Why?
|
| Delivery of Health Care | 3 | 2015 | 948 | 0.480 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2016 | 11 | 0.480 |
Why?
|
| Patient Discharge | 3 | 2022 | 995 | 0.470 |
Why?
|
| Medical Staff, Hospital | 2 | 2013 | 80 | 0.470 |
Why?
|
| Obesity | 6 | 2024 | 3118 | 0.470 |
Why?
|
| Weight Loss | 4 | 2013 | 859 | 0.470 |
Why?
|
| Bayes Theorem | 2 | 2017 | 421 | 0.460 |
Why?
|
| Allografts | 7 | 2021 | 152 | 0.460 |
Why?
|
| Brain Death | 4 | 2026 | 60 | 0.450 |
Why?
|
| Guideline Adherence | 3 | 2019 | 587 | 0.450 |
Why?
|
| Prospective Studies | 24 | 2023 | 8078 | 0.440 |
Why?
|
| Models, Biological | 3 | 2017 | 1764 | 0.440 |
Why?
|
| Comorbidity | 15 | 2025 | 1662 | 0.440 |
Why?
|
| Heart Valve Diseases | 2 | 2016 | 151 | 0.440 |
Why?
|
| Survivors | 2 | 2018 | 523 | 0.440 |
Why?
|
| Metabolic Syndrome | 6 | 2018 | 361 | 0.430 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 143 | 0.430 |
Why?
|
| Hospital Costs | 1 | 2015 | 125 | 0.430 |
Why?
|
| Histocompatibility Testing | 3 | 2024 | 123 | 0.430 |
Why?
|
| Documentation | 2 | 2013 | 199 | 0.420 |
Why?
|
| Models, Theoretical | 2 | 2023 | 560 | 0.420 |
Why?
|
| Referral and Consultation | 3 | 2021 | 869 | 0.420 |
Why?
|
| Medicaid | 3 | 2024 | 467 | 0.420 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 666 | 0.420 |
Why?
|
| Databases, Factual | 11 | 2025 | 1491 | 0.410 |
Why?
|
| Age Factors | 13 | 2021 | 3346 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2019 | 1372 | 0.400 |
Why?
|
| Death | 3 | 2024 | 132 | 0.400 |
Why?
|
| Odds Ratio | 9 | 2019 | 1083 | 0.390 |
Why?
|
| Robotic Surgical Procedures | 2 | 2026 | 185 | 0.390 |
Why?
|
| Testosterone | 2 | 2014 | 416 | 0.390 |
Why?
|
| Methylprednisolone | 1 | 2013 | 59 | 0.380 |
Why?
|
| Nephrologists | 2 | 2023 | 14 | 0.370 |
Why?
|
| Multivariate Analysis | 14 | 2017 | 1547 | 0.370 |
Why?
|
| Disease Progression | 11 | 2025 | 2865 | 0.370 |
Why?
|
| Health Care Rationing | 2 | 2010 | 56 | 0.370 |
Why?
|
| Antilymphocyte Serum | 5 | 2020 | 57 | 0.370 |
Why?
|
| Blood Specimen Collection | 3 | 2017 | 37 | 0.370 |
Why?
|
| Quality of Health Care | 6 | 2023 | 693 | 0.370 |
Why?
|
| Dog Diseases | 2 | 2010 | 106 | 0.360 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 128 | 0.360 |
Why?
|
| Hemolysis | 4 | 2017 | 242 | 0.360 |
Why?
|
| Socioeconomic Factors | 4 | 2024 | 1327 | 0.360 |
Why?
|
| Uric Acid | 5 | 2018 | 167 | 0.360 |
Why?
|
| Income | 4 | 2025 | 203 | 0.360 |
Why?
|
| Insurance, Health | 5 | 2018 | 311 | 0.360 |
Why?
|
| Patient Participation | 3 | 2015 | 446 | 0.360 |
Why?
|
| Inpatients | 2 | 2015 | 553 | 0.350 |
Why?
|
| Clinical Decision-Making | 3 | 2025 | 364 | 0.350 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 241 | 0.350 |
Why?
|
| Community Health Services | 1 | 2013 | 231 | 0.340 |
Why?
|
| Health Status Indicators | 1 | 2012 | 167 | 0.340 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2025 | 3937 | 0.340 |
Why?
|
| Brain Ischemia | 3 | 2020 | 359 | 0.340 |
Why?
|
| Azathioprine | 2 | 2020 | 44 | 0.340 |
Why?
|
| Histocompatibility | 2 | 2017 | 20 | 0.330 |
Why?
|
| Propensity Score | 6 | 2025 | 377 | 0.330 |
Why?
|
| Intensive Care Units | 3 | 2013 | 924 | 0.330 |
Why?
|
| Policy | 2 | 2023 | 149 | 0.330 |
Why?
|
| Creatinine | 9 | 2023 | 515 | 0.320 |
Why?
|
| Sex Factors | 7 | 2024 | 2110 | 0.320 |
Why?
|
| Cat Diseases | 1 | 2010 | 30 | 0.320 |
Why?
|
| Blood Pressure Determination | 4 | 2019 | 145 | 0.320 |
Why?
|
| Government Regulation | 1 | 2010 | 39 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 1505 | 0.310 |
Why?
|
| Laparotomy | 1 | 2010 | 113 | 0.310 |
Why?
|
| Internship and Residency | 3 | 2021 | 1269 | 0.310 |
Why?
|
| Predictive Value of Tests | 9 | 2022 | 2123 | 0.310 |
Why?
|
| Salaries and Fringe Benefits | 3 | 2026 | 58 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 1752 | 0.310 |
Why?
|
| Adipose Tissue | 1 | 2014 | 645 | 0.300 |
Why?
|
| Motor Activity | 1 | 2014 | 718 | 0.300 |
Why?
|
| Models, Statistical | 6 | 2022 | 672 | 0.300 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 821 | 0.290 |
Why?
|
| Apolipoprotein L1 | 2 | 2021 | 14 | 0.290 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 157 | 0.290 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 39 | 0.290 |
Why?
|
| Antibodies | 3 | 2022 | 397 | 0.290 |
Why?
|
| Stroke | 4 | 2020 | 1271 | 0.290 |
Why?
|
| Lithotripsy | 2 | 2019 | 49 | 0.290 |
Why?
|
| Syphilis | 2 | 2022 | 38 | 0.290 |
Why?
|
| Frailty | 2 | 2023 | 205 | 0.290 |
Why?
|
| Calcineurin Inhibitors | 2 | 2008 | 69 | 0.290 |
Why?
|
| Ureter | 2 | 2019 | 36 | 0.290 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 5925 | 0.290 |
Why?
|
| Steroids | 1 | 2009 | 160 | 0.280 |
Why?
|
| Research | 2 | 2010 | 431 | 0.280 |
Why?
|
| Risk | 5 | 2019 | 923 | 0.280 |
Why?
|
| Sirolimus | 6 | 2014 | 282 | 0.270 |
Why?
|
| Machine Learning | 2 | 2025 | 587 | 0.270 |
Why?
|
| Body Weight | 2 | 2009 | 972 | 0.270 |
Why?
|
| Kidney Function Tests | 5 | 2024 | 156 | 0.270 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 910 | 0.270 |
Why?
|
| Fee-for-Service Plans | 2 | 2026 | 99 | 0.260 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 872 | 0.260 |
Why?
|
| Lung | 2 | 2022 | 4116 | 0.260 |
Why?
|
| Child | 15 | 2025 | 22740 | 0.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2017 | 699 | 0.250 |
Why?
|
| Hypertension | 6 | 2017 | 1276 | 0.250 |
Why?
|
| Overweight | 1 | 2012 | 614 | 0.250 |
Why?
|
| Neurologists | 1 | 2026 | 23 | 0.240 |
Why?
|
| Blood Transfusion | 2 | 2025 | 409 | 0.230 |
Why?
|
| ROC Curve | 2 | 2025 | 618 | 0.230 |
Why?
|
| Coronary Angiography | 2 | 2026 | 328 | 0.230 |
Why?
|
| Laparoscopy | 1 | 2010 | 481 | 0.230 |
Why?
|
| Veterans | 1 | 2018 | 1642 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 2602 | 0.230 |
Why?
|
| Warm Ischemia | 1 | 2025 | 19 | 0.230 |
Why?
|
| Transplantation, Homologous | 6 | 2018 | 419 | 0.230 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2026 | 98 | 0.220 |
Why?
|
| Certification | 2 | 2017 | 119 | 0.220 |
Why?
|
| Clinical Coding | 1 | 2025 | 29 | 0.220 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2022 | 611 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2007 | 158 | 0.220 |
Why?
|
| Liver Diseases | 2 | 2024 | 305 | 0.220 |
Why?
|
| Sex Distribution | 2 | 2017 | 388 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2017 | 992 | 0.220 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2021 | 339 | 0.210 |
Why?
|
| Perioperative Period | 2 | 2016 | 71 | 0.210 |
Why?
|
| Computed Tomography Angiography | 1 | 2026 | 146 | 0.210 |
Why?
|
| Chi-Square Distribution | 7 | 2016 | 528 | 0.210 |
Why?
|
| Viremia | 3 | 2014 | 160 | 0.210 |
Why?
|
| Fructose | 2 | 2018 | 132 | 0.210 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 415 | 0.200 |
Why?
|
| Patient Navigation | 2 | 2017 | 126 | 0.200 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 3418 | 0.200 |
Why?
|
| Quality of Life | 5 | 2022 | 3211 | 0.200 |
Why?
|
| Calibration | 1 | 2024 | 152 | 0.200 |
Why?
|
| Child, Preschool | 8 | 2025 | 11868 | 0.200 |
Why?
|
| Research Design | 2 | 2017 | 1139 | 0.200 |
Why?
|
| Hepatitis C | 2 | 2025 | 256 | 0.200 |
Why?
|
| Insurance Coverage | 3 | 2016 | 244 | 0.200 |
Why?
|
| Blood Pressure | 4 | 2019 | 1782 | 0.190 |
Why?
|
| Costs and Cost Analysis | 4 | 2024 | 221 | 0.190 |
Why?
|
| Ureteroscopy | 2 | 2019 | 15 | 0.190 |
Why?
|
| Swine | 1 | 2025 | 826 | 0.190 |
Why?
|
| Waist Circumference | 2 | 2014 | 143 | 0.190 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2023 | 104 | 0.190 |
Why?
|
| Chronic Disease | 9 | 2024 | 1812 | 0.180 |
Why?
|
| Chlamydia | 1 | 2022 | 8 | 0.180 |
Why?
|
| Transplantation Conditioning | 3 | 2009 | 191 | 0.180 |
Why?
|
| Information Dissemination | 1 | 2024 | 224 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 1420 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 3 | 2017 | 269 | 0.180 |
Why?
|
| Hospital Charges | 2 | 2019 | 46 | 0.180 |
Why?
|
| Pandemics | 2 | 2021 | 1711 | 0.180 |
Why?
|
| Data Collection | 1 | 2025 | 643 | 0.180 |
Why?
|
| Diabetic Nephropathies | 3 | 2017 | 322 | 0.170 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 777 | 0.170 |
Why?
|
| Cytomegalovirus | 4 | 2024 | 168 | 0.170 |
Why?
|
| Stomach Diseases | 1 | 2021 | 20 | 0.170 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 12 | 0.170 |
Why?
|
| Urologic Diseases | 2 | 2019 | 42 | 0.170 |
Why?
|
| Alemtuzumab | 3 | 2017 | 15 | 0.170 |
Why?
|
| Histamine H2 Antagonists | 1 | 2021 | 23 | 0.170 |
Why?
|
| Gonorrhea | 1 | 2022 | 63 | 0.170 |
Why?
|
| Family | 2 | 2024 | 685 | 0.170 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 79 | 0.170 |
Why?
|
| Motivation | 2 | 2016 | 602 | 0.170 |
Why?
|
| Defibrillators, Implantable | 2 | 2015 | 387 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 1 | 2022 | 99 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1582 | 0.160 |
Why?
|
| Proteinuria | 1 | 2021 | 104 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 368 | 0.160 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 109 | 0.160 |
Why?
|
| Podocytes | 1 | 2021 | 80 | 0.160 |
Why?
|
| Abdominal Fat | 1 | 2020 | 51 | 0.150 |
Why?
|
| Nephrolithotomy, Percutaneous | 1 | 2019 | 5 | 0.150 |
Why?
|
| Insurance Benefits | 1 | 2019 | 12 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 381 | 0.150 |
Why?
|
| Liver | 3 | 2023 | 1899 | 0.150 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 168 | 0.150 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 544 | 0.150 |
Why?
|
| Job Satisfaction | 1 | 2022 | 238 | 0.150 |
Why?
|
| Acute Disease | 5 | 2017 | 1036 | 0.150 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 91 | 0.150 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 129 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 171 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2010 | 1378 | 0.150 |
Why?
|
| Health Facility Administration | 2 | 2010 | 7 | 0.150 |
Why?
|
| Magnesium | 1 | 2020 | 157 | 0.150 |
Why?
|
| Coronary Artery Disease | 1 | 2026 | 750 | 0.150 |
Why?
|
| Ureteral Calculi | 1 | 2019 | 15 | 0.150 |
Why?
|
| Myocardial Revascularization | 2 | 2016 | 85 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2019 | 78 | 0.150 |
Why?
|
| Triticum | 1 | 2019 | 18 | 0.140 |
Why?
|
| Infant | 7 | 2025 | 10091 | 0.140 |
Why?
|
| Decision Trees | 1 | 2019 | 78 | 0.140 |
Why?
|
| Viral Load | 3 | 2016 | 526 | 0.140 |
Why?
|
| Career Choice | 1 | 2021 | 235 | 0.140 |
Why?
|
| Biomarkers | 7 | 2020 | 4302 | 0.140 |
Why?
|
| Risk Adjustment | 2 | 2010 | 85 | 0.140 |
Why?
|
| Adiposity | 2 | 2014 | 532 | 0.140 |
Why?
|
| Length of Stay | 4 | 2026 | 1350 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 164 | 0.140 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 390 | 0.140 |
Why?
|
| Medical Futility | 1 | 2018 | 32 | 0.140 |
Why?
|
| Biopsy | 4 | 2021 | 1082 | 0.140 |
Why?
|
| Patient Admission | 1 | 2020 | 220 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 920 | 0.140 |
Why?
|
| Internal Medicine | 1 | 2021 | 279 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 2968 | 0.140 |
Why?
|
| Stroke Volume | 2 | 2019 | 655 | 0.130 |
Why?
|
| Health Care Costs | 2 | 2020 | 425 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2020 | 260 | 0.130 |
Why?
|
| Killer Cells, Natural | 2 | 2014 | 481 | 0.130 |
Why?
|
| Heat-Shock Response | 1 | 2018 | 77 | 0.130 |
Why?
|
| Prevalence | 6 | 2026 | 2875 | 0.130 |
Why?
|
| Hypotension | 1 | 2019 | 127 | 0.130 |
Why?
|
| Gout Suppressants | 1 | 2017 | 19 | 0.130 |
Why?
|
| Phlebotomy | 1 | 2017 | 22 | 0.130 |
Why?
|
| Hyperuricemia | 1 | 2017 | 47 | 0.130 |
Why?
|
| Diabetes Complications | 3 | 2009 | 225 | 0.130 |
Why?
|
| Hypernatremia | 1 | 2017 | 8 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2020 | 211 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2019 | 259 | 0.130 |
Why?
|
| Health Records, Personal | 1 | 2017 | 26 | 0.130 |
Why?
|
| Aftercare | 1 | 2019 | 222 | 0.130 |
Why?
|
| Vitamin D | 2 | 2011 | 404 | 0.130 |
Why?
|
| Employment | 2 | 2016 | 184 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 201 | 0.130 |
Why?
|
| Heart Valve Prosthesis | 1 | 2019 | 129 | 0.130 |
Why?
|
| Hyponatremia | 1 | 2017 | 43 | 0.130 |
Why?
|
| Dendritic Cells | 3 | 2005 | 501 | 0.130 |
Why?
|
| Body Image | 1 | 2018 | 96 | 0.120 |
Why?
|
| Fatigue | 1 | 2019 | 366 | 0.120 |
Why?
|
| Drug Overdose | 1 | 2021 | 375 | 0.120 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 154 | 0.120 |
Why?
|
| Treponema pallidum | 1 | 2016 | 10 | 0.120 |
Why?
|
| Financing, Personal | 1 | 2016 | 27 | 0.120 |
Why?
|
| Laboratories, Hospital | 1 | 2016 | 14 | 0.120 |
Why?
|
| Case-Control Studies | 6 | 2022 | 3634 | 0.120 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 489 | 0.120 |
Why?
|
| Parental Leave | 1 | 2016 | 27 | 0.120 |
Why?
|
| Graft vs Host Disease | 4 | 2008 | 279 | 0.120 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 64 | 0.120 |
Why?
|
| Patient Preference | 1 | 2018 | 223 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 256 | 0.110 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 119 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 364 | 0.110 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 221 | 0.110 |
Why?
|
| Hospitals, General | 1 | 2015 | 25 | 0.110 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 6085 | 0.110 |
Why?
|
| Hypokalemia | 1 | 2015 | 24 | 0.110 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 1154 | 0.110 |
Why?
|
| Contrast Media | 1 | 2018 | 497 | 0.110 |
Why?
|
| Regression Analysis | 3 | 2014 | 1001 | 0.110 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 141 | 0.110 |
Why?
|
| Affect | 1 | 2018 | 321 | 0.110 |
Why?
|
| Stents | 1 | 2019 | 564 | 0.110 |
Why?
|
| Hyperkalemia | 1 | 2015 | 36 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 88 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2016 | 183 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 1043 | 0.110 |
Why?
|
| Catheters | 1 | 2015 | 74 | 0.110 |
Why?
|
| Reimbursement Mechanisms | 1 | 2015 | 79 | 0.110 |
Why?
|
| Equipment Design | 1 | 2016 | 525 | 0.110 |
Why?
|
| Electric Countershock | 1 | 2015 | 126 | 0.110 |
Why?
|
| Fear | 1 | 2018 | 368 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 285 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 288 | 0.100 |
Why?
|
| Information Services | 1 | 2014 | 43 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 544 | 0.100 |
Why?
|
| Hemodialysis, Home | 1 | 2014 | 9 | 0.100 |
Why?
|
| Algorithms | 3 | 2022 | 1851 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 268 | 0.100 |
Why?
|
| Chelating Agents | 1 | 2014 | 76 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 644 | 0.100 |
Why?
|
| HIV Infections | 2 | 2022 | 3195 | 0.100 |
Why?
|
| Intention | 2 | 2015 | 186 | 0.100 |
Why?
|
| Vascular Resistance | 1 | 2015 | 370 | 0.100 |
Why?
|
| HLA-C Antigens | 1 | 2014 | 37 | 0.100 |
Why?
|
| Selection Bias | 2 | 2010 | 38 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 98 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 779 | 0.100 |
Why?
|
| Health Status | 3 | 2021 | 835 | 0.100 |
Why?
|
| Phosphates | 1 | 2014 | 177 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 883 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2015 | 222 | 0.100 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 237 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 66 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2016 | 373 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2015 | 180 | 0.100 |
Why?
|
| Florida | 2 | 2011 | 117 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 71 | 0.100 |
Why?
|
| Patients | 1 | 2015 | 183 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 605 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 981 | 0.100 |
Why?
|
| Urologic Surgical Procedures | 1 | 2014 | 118 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 1043 | 0.090 |
Why?
|
| Receptors, KIR | 1 | 2014 | 118 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2019 | 782 | 0.090 |
Why?
|
| Program Development | 1 | 2015 | 368 | 0.090 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 11 | 0.090 |
Why?
|
| House Calls | 1 | 2014 | 154 | 0.090 |
Why?
|
| HLA-DQ Antigens | 2 | 2024 | 174 | 0.090 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 144 | 0.090 |
Why?
|
| Hypoalbuminemia | 1 | 2012 | 27 | 0.090 |
Why?
|
| Palliative Care | 1 | 2021 | 1022 | 0.090 |
Why?
|
| Public Health | 1 | 2017 | 574 | 0.090 |
Why?
|
| Triglycerides | 2 | 2012 | 520 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 356 | 0.090 |
Why?
|
| Breast Feeding | 1 | 2016 | 447 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 335 | 0.090 |
Why?
|
| Peritoneal Dialysis | 1 | 2014 | 100 | 0.090 |
Why?
|
| Dogs | 2 | 2010 | 478 | 0.090 |
Why?
|
| Whole-Body Irradiation | 2 | 2009 | 74 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 558 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 394 | 0.090 |
Why?
|
| Anthropometry | 1 | 2012 | 206 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 96 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2020 | 1244 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2017 | 977 | 0.090 |
Why?
|
| Quality Control | 2 | 2016 | 161 | 0.090 |
Why?
|
| Animals | 5 | 2025 | 38102 | 0.090 |
Why?
|
| Bicarbonates | 1 | 2011 | 45 | 0.090 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 29 | 0.080 |
Why?
|
| Skin | 1 | 2016 | 754 | 0.080 |
Why?
|
| Herpesviridae Infections | 1 | 2012 | 148 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2017 | 697 | 0.080 |
Why?
|
| Hypophosphatemia | 1 | 2011 | 17 | 0.080 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 1197 | 0.080 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 1101 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2011 | 176 | 0.080 |
Why?
|
| International Classification of Diseases | 2 | 2022 | 150 | 0.080 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 235 | 0.080 |
Why?
|
| Renin | 1 | 2010 | 33 | 0.080 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2010 | 18 | 0.080 |
Why?
|
| Glomerulonephritis | 1 | 2010 | 44 | 0.080 |
Why?
|
| Physical Phenomena | 1 | 2010 | 13 | 0.080 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 549 | 0.080 |
Why?
|
| Caloric Restriction | 1 | 2012 | 133 | 0.080 |
Why?
|
| Cats | 1 | 2010 | 234 | 0.080 |
Why?
|
| Cyclosporine | 3 | 2011 | 256 | 0.080 |
Why?
|
| Urban Population | 1 | 2013 | 494 | 0.080 |
Why?
|
| Virus Activation | 2 | 2013 | 94 | 0.080 |
Why?
|
| Inflammation | 2 | 2020 | 2884 | 0.080 |
Why?
|
| Mothers | 1 | 2016 | 766 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2009 | 21 | 0.080 |
Why?
|
| Polycythemia | 1 | 2010 | 25 | 0.080 |
Why?
|
| Organizational Innovation | 1 | 2010 | 119 | 0.080 |
Why?
|
| Allopurinol | 1 | 2009 | 70 | 0.080 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2009 | 5 | 0.080 |
Why?
|
| Heart Block | 1 | 2009 | 41 | 0.070 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2009 | 30 | 0.070 |
Why?
|
| Myeloablative Agonists | 1 | 2009 | 23 | 0.070 |
Why?
|
| National Health Programs | 1 | 2009 | 23 | 0.070 |
Why?
|
| Busulfan | 1 | 2009 | 15 | 0.070 |
Why?
|
| Vidarabine | 1 | 2009 | 32 | 0.070 |
Why?
|
| Least-Squares Analysis | 1 | 2009 | 73 | 0.070 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 190 | 0.070 |
Why?
|
| Topography, Medical | 1 | 2009 | 10 | 0.070 |
Why?
|
| Health Behavior | 1 | 2015 | 791 | 0.070 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 343 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 106 | 0.070 |
Why?
|
| Energy Intake | 1 | 2012 | 512 | 0.070 |
Why?
|
| Rural Population | 1 | 2013 | 661 | 0.070 |
Why?
|
| United Kingdom | 1 | 2009 | 358 | 0.070 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 128 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 712 | 0.070 |
Why?
|
| Models, Economic | 1 | 2008 | 62 | 0.070 |
Why?
|
| Minority Groups | 1 | 2010 | 285 | 0.070 |
Why?
|
| Recurrence | 4 | 2021 | 1139 | 0.070 |
Why?
|
| Control Groups | 1 | 2007 | 12 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 327 | 0.060 |
Why?
|
| Health Care Surveys | 2 | 2021 | 536 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1271 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 2006 | 22 | 0.060 |
Why?
|
| Patient Care | 1 | 2007 | 120 | 0.060 |
Why?
|
| Naphthalenes | 1 | 2006 | 54 | 0.060 |
Why?
|
| Transportation | 2 | 2016 | 57 | 0.060 |
Why?
|
| Accreditation | 1 | 2006 | 101 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2009 | 6465 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 404 | 0.060 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 61 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2005 | 115 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1998 | 0.050 |
Why?
|
| Leukocytes | 1 | 2006 | 296 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2011 | 719 | 0.050 |
Why?
|
| Antigens | 1 | 2006 | 348 | 0.050 |
Why?
|
| Critical Illness | 1 | 2011 | 900 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2005 | 113 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 189 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 171 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2006 | 247 | 0.050 |
Why?
|
| Foundations | 1 | 2024 | 27 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2004 | 80 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 274 | 0.050 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 202 | 0.050 |
Why?
|
| Heterografts | 1 | 2024 | 143 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2020 | 1300 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2024 | 72 | 0.050 |
Why?
|
| Lithium | 1 | 2023 | 40 | 0.050 |
Why?
|
| Leukemia | 1 | 2005 | 246 | 0.050 |
Why?
|
| Arterial Pressure | 2 | 2014 | 134 | 0.050 |
Why?
|
| Diet | 1 | 2010 | 1278 | 0.050 |
Why?
|
| Shock | 1 | 2024 | 110 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 83 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 1957 | 0.050 |
Why?
|
| Phosphorus | 2 | 2014 | 90 | 0.040 |
Why?
|
| Laboratories | 1 | 2023 | 110 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2219 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 288 | 0.040 |
Why?
|
| Educational Status | 1 | 2024 | 470 | 0.040 |
Why?
|
| Relative Value Scales | 1 | 2021 | 6 | 0.040 |
Why?
|
| Microscopy | 1 | 2023 | 147 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 198 | 0.040 |
Why?
|
| Health Equity | 1 | 2024 | 133 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2022 | 332 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2021 | 138 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2021 | 39 | 0.040 |
Why?
|
| Brazil | 1 | 2021 | 179 | 0.040 |
Why?
|
| Work-Life Balance | 1 | 2021 | 22 | 0.040 |
Why?
|
| Health Personnel | 1 | 2008 | 757 | 0.040 |
Why?
|
| Recovery of Function | 2 | 2019 | 716 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 896 | 0.040 |
Why?
|
| HIV | 1 | 2022 | 251 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1217 | 0.040 |
Why?
|
| Workload | 1 | 2022 | 169 | 0.040 |
Why?
|
| Databases as Topic | 3 | 2005 | 71 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 421 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2008 | 770 | 0.040 |
Why?
|
| United States Public Health Service | 1 | 2019 | 9 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 197 | 0.040 |
Why?
|
| Probability | 1 | 2020 | 308 | 0.040 |
Why?
|
| Exercise | 1 | 2012 | 2205 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 226 | 0.040 |
Why?
|
| Clinical Clerkship | 1 | 2021 | 109 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2023 | 1003 | 0.040 |
Why?
|
| Calcium Oxalate | 1 | 2018 | 7 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2018 | 26 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 217 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 134 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 351 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2005 | 878 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 100 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 197 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2020 | 618 | 0.030 |
Why?
|
| Linear Models | 1 | 2020 | 849 | 0.030 |
Why?
|
| Autografts | 1 | 2017 | 55 | 0.030 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2017 | 8 | 0.030 |
Why?
|
| Terminal Care | 1 | 2021 | 283 | 0.030 |
Why?
|
| Hematologic Neoplasms | 2 | 2009 | 168 | 0.030 |
Why?
|
| Reference Values | 2 | 2011 | 798 | 0.030 |
Why?
|
| Silver Staining | 1 | 2016 | 16 | 0.030 |
Why?
|
| Lipids | 2 | 2013 | 707 | 0.030 |
Why?
|
| Calcium | 2 | 2014 | 1191 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2014 | 1898 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 900 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2770 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 168 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 653 | 0.030 |
Why?
|
| Genotype | 1 | 2021 | 1857 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 280 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 648 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2019 | 364 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 99 | 0.030 |
Why?
|
| Potassium | 1 | 2015 | 152 | 0.030 |
Why?
|
| Lumbosacral Region | 1 | 2015 | 59 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 78 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 115 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2015 | 115 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 126 | 0.030 |
Why?
|
| Housing | 1 | 2015 | 142 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 360 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 149 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 61 | 0.030 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2014 | 16 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 229 | 0.030 |
Why?
|
| Cell Count | 2 | 2005 | 319 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2014 | 67 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2015 | 91 | 0.020 |
Why?
|
| Hypogonadism | 1 | 2014 | 93 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2016 | 382 | 0.020 |
Why?
|
| Mass Screening | 1 | 2022 | 1361 | 0.020 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 152 | 0.020 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2013 | 10 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 280 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 521 | 0.020 |
Why?
|
| Organ Size | 1 | 2014 | 461 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2015 | 356 | 0.020 |
Why?
|
| Consensus | 1 | 2015 | 479 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2012 | 9 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2012 | 31 | 0.020 |
Why?
|
| Medical Audit | 1 | 2013 | 77 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 306 | 0.020 |
Why?
|
| Health Literacy | 1 | 2015 | 186 | 0.020 |
Why?
|
| Health Services | 1 | 2013 | 113 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2014 | 386 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2005 | 1165 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 1180 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2013 | 2344 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2013 | 184 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2015 | 916 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 486 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 109 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 456 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 120 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 114 | 0.020 |
Why?
|
| Natriuretic Agents | 1 | 2009 | 2 | 0.020 |
Why?
|
| Aneurysm | 1 | 2009 | 37 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 69 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 188 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2011 | 142 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 782 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 289 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2009 | 109 | 0.020 |
Why?
|
| Diethylamines | 1 | 2008 | 5 | 0.020 |
Why?
|
| Blood Cells | 1 | 2008 | 38 | 0.020 |
Why?
|
| Chromones | 1 | 2008 | 43 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1477 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 538 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 714 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 165 | 0.020 |
Why?
|
| Communication | 1 | 2015 | 977 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 279 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 484 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 280 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2000 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 27 | 0.020 |
Why?
|
| HLA-DP Antigens | 1 | 2007 | 32 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2007 | 52 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 396 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2015 | 1683 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 2028 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2009 | 380 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2017 | 1737 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 584 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2009 | 668 | 0.010 |
Why?
|
| Physicians | 1 | 2015 | 956 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2009 | 756 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 3170 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 37 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7216 | 0.010 |
Why?
|
| Critical Care | 1 | 2009 | 702 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 892 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 322 | 0.010 |
Why?
|
| Neoplasms | 1 | 2018 | 2913 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 962 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 674 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 630 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 2516 | 0.010 |
Why?
|